Tenax Therapeutics, Inc. (TENX) Stock

Tenax Therapeutics, Inc. (TENX) is a Healthcare stock trading at $1.75 (as of 2026-08-21), with a market capitalization of $46.42M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company developing and commercializing therapies for cardiovascular and pulmonary diseases in the United States and Canada. Its pipeline includes TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension associated with heart failure with preserved ejection fraction, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Valuation — source: SEC EDGAR (first-party)
Price$1.75
Market Cap$46.42M
Price / Book0.41
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Financial Health — source: SEC EDGAR
Altman Z-Score-3.08 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJANUS HENDERSON GROUP PLC ($29.07M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOChristopher T. Giordano
Employees4
CountryUS
IPO Date1994-04-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • TransCode Therapeutics, Inc. (RNAZ)
  • Hyperion DeFi, Inc. (HYPD)
  • Grace Therapeutics, Inc. (GRCE)
  • FILANA THERAPEUTICS, INC. (FLNA)
  • Seres Therapeutics, Inc. (MCRB)
  • Karyopharm Therapeutics Inc. (KPTI)
  • Silo Pharma, Inc. (SILO)
  • Veru Inc. (VERU)
TENX earnings history · TENX institutional & insider holders · TENX KPIs & operating metrics · TENX financials · TENX investor presentations & press releases · TENX SEC filings · TENX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.